Screener
Gilead Sciences GILD Rest of World — Total revenues
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Europe | Three Months Ended June 30, 2026 / Rest of World | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Europe | Three Months Ended June 30, 2025 / Rest of World | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|
| Total Oncology | 468 | 265 | 140 | 873 | 427 | 291 | 131 | 849 |
| Other | ||||||||
| AmBisome | 4 | 47 | 59 | 110 | 7 | 65 | 56 | 129 |
| Other(5) | 22 | 8 | 21 | 51 | 44 | 8 | 21 | 73 |
| Total Other | 26 | 55 | 80 | 161 | 52 | 73 | 77 | 202 |
| Total product sales | 5,601 | 1,155 | 872 | 7,627 | 5,038 | 1,178 | 838 | 7,054 |
| Royalty, contract and other revenues | 2 | 169 | 4 | 176 | 13 | 10 | 4 | 27 |
| Total revenues | $5,603 | $1,324 | $876 | $7,803 | $5,051 | $1,189 | $842 | $7,082 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's rest of world — total revenues?
- Gilead Sciences (GILD) reported rest of world — total revenues of $876M in Q2 2026.
- How has Gilead Sciences's rest of world — total revenues changed year-over-year?
- Gilead Sciences's rest of world — total revenues increased by 4.0% year-over-year, from $842M to $876M.
- What is the long-term trend for Gilead Sciences's rest of world — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's rest of world — total revenues has grown at a -3.7% compound annual growth rate (CAGR), from $3.93B to $3.5B.
- What does rest of world — total revenues mean?
- This metric represents the total gross revenue generated from pharmaceutical product sales and related services within geographic regions outside of the company's primary domestic and major international markets. It captures the performance of the company's therapeutic portfolio in diverse global territories, reflecting market penetration and regulatory success in these specific regions. Monitoring this segment helps investors assess the company's global footprint and its ability to diversify revenue streams beyond its core operating hubs.
Ask your AI about Gilead Sciences's rest of world — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude